News
Gain insights into Biofrontera Inc.'s Q1 2025 earnings call with updates on revenue growth, cost discipline, a new Ameluz patent, and key clinical milestones.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback